Qpex Biopharma Inc., a Shionogi Group Company, is a clinical-stage biopharmaceutical company committed to improving patient care across inpatient and outpatient settings. With a robust portfolio of potential best-in-class, clinical-stage products, the companyโs lead program is based on xeruborbactam, an investigational beta-lactamase inhibitor discovered by Qpex scientists.
Our expertise in drug discovery, development and regulatory approval leverages decades of knowledge around drug resistance mechanisms and translational pharmacology. Itโs the foundation for our goal to meet the needs of patients with improvements to current anti-infectives.
In 2023, we expanded our infectious disease R&D capabilities through our acquisition by Shionogi. This brought together our novel pipelines and experienced and specialized team of infectious disease researchers with over 25 years of innovation with an established global R&D organization. Recently, Qpex and Shionogi extended our commitment to ongoing innovation in infectious disease by expanding the combined R&D capabilities for both companies in San Diego, California.
Today weโre committed to advancing science with the urgency that infectious diseases demand. Through a combination of in-house discovery and strategic partnerships with government, academia and industry, Qpex and Shionogi are working to address unmet medical needs in infectious disease for patients worldwide.
